Orchestra BioMed Holdings, Inc. Operating Income
Orchestra BioMed Holdings, Inc. (OBIO) reported Operating Income of -$22.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$22.36M.
- Orchestra BioMed Holdings, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$22.08M.
- Orchestra BioMed Holdings, Inc. operating income (loss) for the quarter ending 2025-12-31 was $6.75M.
- Orchestra BioMed Holdings, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$20.31M.
- Orchestra BioMed Holdings, Inc. operating income (loss) for fiscal 2025 was -$51.81M.
- Orchestra BioMed Holdings, Inc. operating income (loss) for fiscal 2024 was -$64.30M.
- Orchestra BioMed Holdings, Inc. operating income (loss) for fiscal 2023 was -$51.51M.
- Orchestra BioMed Holdings, Inc. operating income (loss) for fiscal 2022 was -$32.66M.
| Period end | Operating Income (Loss) 1 month | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 4 month | Operating Income (Loss) 4 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 7 month | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$22.36M 10-Q · filed 2026-08-10 | -$44.43M 10-Q · filed 2026-08-10 | -$37.68M derived: sum of 3 quarters · filed 2026-08-10 | -$57.99M derived: sum of 4 quarters · filed 2026-08-10 | ||||||||
| 2026-03-31 | -$22.08M 10-Q · filed 2026-05-12 | -$15.32M derived: sum of 2 quarters · filed 2026-05-12 | -$35.63M derived: sum of 3 quarters · filed 2026-05-12 | -$54.96M derived: sum of 4 quarters · filed 2026-08-10 | ||||||||
| 2025-12-31 | $6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$13.56M derived: sum of 2 quarters · filed 2026-03-12 | -$32.89M derived: sum of 3 quarters · filed 2026-08-10 | -$51.81M 10-K · filed 2026-03-12 | ||||||||
| 2025-09-30 | -$20.31M 10-Q · filed 2025-11-10 | -$39.64M derived: sum of 2 quarters · filed 2026-08-10 | -$58.56M 10-Q · filed 2025-11-10 | -$75.24M derived: sum of 4 quarters · filed 2026-08-10 | ||||||||
| 2025-06-30 | -$19.33M 10-Q · filed 2026-08-10 | -$38.25M 10-Q · filed 2026-08-10 | -$54.92M derived: sum of 3 quarters · filed 2026-08-10 | -$71.27M derived: sum of 4 quarters · filed 2026-08-10 | ||||||||
| 2025-03-31 | -$18.92M 10-Q · filed 2026-05-12 | -$35.60M derived: sum of 2 quarters · filed 2026-05-12 | -$51.94M derived: sum of 3 quarters · filed 2026-05-12 | -$68.80M derived: sum of 4 quarters · filed 2026-05-12 | ||||||||
| 2024-12-31 | -$16.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$33.02M derived: sum of 2 quarters · filed 2026-03-12 | -$49.88M derived: sum of 3 quarters · filed 2026-03-12 | -$64.30M 10-K · filed 2026-03-12 | ||||||||
| 2024-09-30 | -$16.34M 10-Q · filed 2025-11-10 | -$33.20M derived: sum of 2 quarters · filed 2025-11-10 | -$47.62M 10-Q · filed 2025-11-10 | -$60.10M derived: sum of 4 quarters · filed 2025-11-10 | ||||||||
| 2024-06-30 | -$16.86M 10-Q · filed 2025-08-12 | -$31.28M 10-Q · filed 2025-08-12 | -$43.76M derived: sum of 3 quarters · filed 2025-08-12 | -$58.29M derived: sum of 4 quarters · filed 2025-08-12 | ||||||||
| 2024-03-31 | -$14.42M 10-Q · filed 2025-05-12 | -$26.90M derived: sum of 2 quarters · filed 2025-05-12 | -$41.43M derived: sum of 3 quarters · filed 2025-05-12 | -$54.38M derived: sum of 4 quarters · filed 2025-05-12 | ||||||||
| 2023-12-31 | -$12.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$27.00M derived: sum of 2 quarters · filed 2025-03-31 | -$39.96M derived: sum of 3 quarters · filed 2025-03-31 | -$51.51M 10-K · filed 2025-03-31 | ||||||||
| 2023-09-30 | -$14.52M 10-Q · filed 2024-11-12 | -$27.48M derived: sum of 2 quarters · filed 2024-11-12 | -$39.02M 10-Q · filed 2024-11-12 | -$48.85M derived: sum of 4 quarters · filed 2024-11-12 | ||||||||
| 2023-06-30 | -$12.96M 10-Q · filed 2024-08-12 | -$24.50M 10-Q · filed 2024-08-12 | -$34.33M derived: sum of 3 quarters · filed 2024-08-12 | -$44.40M derived: sum of 4 quarters · filed 2024-08-12 | ||||||||
| 2023-03-31 | -$11.54M 10-Q · filed 2024-05-13 | -$21.37M derived: sum of 2 quarters · filed 2024-05-13 | -$31.44M derived: sum of 3 quarters · filed 2024-05-13 | -$39.07M derived: sum of 4 quarters · filed 2024-05-13 | ||||||||
| 2022-12-31 | -$9.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$19.89M derived: sum of 2 quarters · filed 2024-03-27 | -$27.53M derived: sum of 3 quarters · filed 2024-03-27 | -$32.66M 10-K · filed 2024-03-27 | -$3.08M 10-K · filed 2023-01-25 | |||||||
| 2022-09-30 | -$10.07M 10-Q · filed 2023-11-13 | -$813.41K 10-Q · filed 2022-11-14 | -$17.70M derived: sum of 2 quarters · filed 2023-11-13 | -$22.83M 10-Q · filed 2023-11-13 | -$2.20M 10-Q · filed 2022-11-14 | -$22.92M derived: sum of 4 quarters · filed 2023-11-13 | ||||||
| 2022-06-30 | -$7.63M 10-Q · filed 2023-08-10 | -$938.17K 10-Q · filed 2022-08-15 | -$12.76M 10-Q · filed 2023-08-10 | -$1.39M 10-Q · filed 2022-08-15 | -$12.85M derived: sum of 3 quarters · filed 2023-08-10 | -$12.95M derived: sum of 4 quarters · filed 2023-08-10 | ||||||
| 2022-03-31 | -$5.13M 10-Q · filed 2023-05-12 | -$451.95K 10-Q · filed 2022-05-13 | -$5.22M derived: sum of 2 quarters · filed 2023-05-12 | -$5.31M derived: sum of 3 quarters · filed 2023-05-12 | -$5.41M derived: sum of 4 quarters · filed 2023-05-12 | |||||||
| 2021-12-31 | -$92.05K derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-25 | -$186.49K derived: sum of 2 quarters · filed 2023-01-25 | -$282.81K derived: sum of 3 quarters · filed 2023-01-25 | -$394.76K 10-K · filed 2023-01-25 | ||||||||
| 2021-09-30 | -$94.44K 10-Q · filed 2022-11-14 | -$190.76K derived: sum of 2 quarters · filed 2022-11-14 | -$302.71K 10-Q · filed 2022-11-14 | |||||||||
| 2021-06-30 | -$96.32K 10-Q · filed 2022-08-15 | -$208.27K 10-Q · filed 2022-08-15 | ||||||||||
| 2021-03-31 | -$111.95K 10-Q · filed 2022-05-13 | |||||||||||
| 2020-12-31 | -$179.99K 10-K · filed 2022-03-31 | |||||||||||
| 2020-09-30 | -$68.63K 10-Q/A · filed 2022-03-31 | -$83.84K 10-Q/A · filed 2022-03-31 | $83.84K 10-Q · filed 2021-11-12 | |||||||||
| 2020-06-30 | -$15.21K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |